OBIO CAAP Company CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial

CellAegis Devices announced enrollment of the first patients in a U.S. clinical trial of its autoRIC® device. The autoRIC® device automatically delivers remote ischemic conditioning to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures. 

Click here to read the full release

Previous
Previous

VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study

Next
Next

Impact Centre: Report on Physical Technologies Forum